Leslie Parise, PhD – Co-founder
Leslie Parise is Professor and Chair of the Department of Biochemistry and Biophysics at The University of North Carolina at Chapel Hill (UNC). Dr. Parise has a longstanding interest in cancer research and is a member of the Lineberger Comprehensive Cancer Center. Dr. Parise is also widely respected researcher in platelet and integrin biology and biochemistry. She is an AAAS Fellow, associate editor for the journal Blood, and a member of the Advisory Committee for the American Society of Biochemistry and Molecular Biology.
Dr. Parise received a BS in Chemistry from University of Illinois at Urbana-Champaign, PhD in Pharmacology from the University of Illinois Medical at Chicago, and postdoctoral training at the University of California San Francisco.
Tina Leisner, PhD – Co-founder
Tina Leisner is a Research Specialist in the UNC Department of Biochemistry and Biophysics. She performed the original work to identify novel therapeutic targets in TNBC, and leads Reveris’ efforts to develop small molecule inhibitors to treat TNBC. Drs. Leisner and Parise have worked together for over 15 years.
Dr. Leisner received a BS from Northern Illinois University and PhD in Pharmacology from the University of Illinois at Chicago.
Justin Black, PhD – Co-founder
Justin Black was a doctoral candidate in the UNC Department of Biochemistry and Biophysics. Mr. Black’s graduate dissertation research confirmed Reveris’ technology in TNBC in vivo. He also carried out initial market research and developed a preliminary commercialization strategy for Reveris.
Dr. Black received his BS in molecular biology from Brigham Young University, and PhD in Biochemistry from the University of North Carolina at Chapel Hill in 2015.
Don Rose is Director of Carolina Kickstart, and brings more than 20 years of experience in industry research, entrepreneurship, venture capital, and advising University startups.
Dr. Rose received his BS in Nutrition and PhD in Analytical Chemistry from the University of North Carolina at Chapel Hill.
Dale Christensen has 20+ years of research experience at the interface of chemistry and biology, with senior positions at Oncotide, Cognosci, Affinergy Inc., Aryzun Pharmaceuticals, and KaroBio USA, formerly Novalon.
Dr. Christensen received his BS in Chemistry from Utah State University, and a Ph.D. in Organic Chemistry from the University of Utah.